

0040-4039(95)02290-2

FACILE ASYMMETRIC SYNTHESIS OF THE D-MYO-INOSITOL DERIVATIVE FROM DIETHYL 2,3-O-ISOPROPYLIDENE-D-TARTRATE

Takayuki Sawada, Ryuichi Shirai and Shigeo Iwasaki*

*Institute of Molecular and Cellular Biosciences (IMCB),
 The University of Tokyo,
 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113, Japan.*


Abstract: A facile asymmetric synthesis of the D-*myo*-inositol derivative was achieved from diethyl 2,3-*O*-isopropylidene-D-tartrate in 7 steps. The two carboxylate groups of diethyl tartrate were converted simultaneously into dialdehyde to afford a key intermediate (**1**) for the synthesis of various protected D-*myo*-inositols.

Polyphosphoinositides play significant roles in the cellular signal transduction systems¹. Phosphatidyl-D-*myo*-inositol 4,5-bisphosphate is hydrolyzed by phospholipase C, which is activated on stimulation with many growth factors, to give diacylglycerol and D-*myo*-inositol 1,4,5-trisphosphate. Then diacylglycerol activates protein kinase C and D-*myo*-inositol 1,4,5-trisphosphate promotes release of intracellular Ca²⁺. In addition, PI-3 kinase phosphorylates phosphatidyl-D-*myo*-inositol 4,5-bisphosphate to phosphatidyl-D-*myo*-inositol 3,4,5-trisphosphate, which may act as a second messenger in cellular signal transduction².


Since the supply of polyphosphoinositides from natural sources is very limited, extensive efforts have been made to synthesize racemic and homochiral inositol derivatives¹. Recently we synthesized 1-*O*-alkyl- and 1-*O*-acyl-D-*myo*-inositol 3,4,5-trisphosphates as new analogues of phosphatidyl-D-*myo*-inositol 3,4,5-trisphosphate³. Here we describe a highly efficient asymmetric synthesis of enantiomerically pure inositol derivatives from diethyltartrate.

In 1987, Ozaki and co-workers^{4a} reported the synthesis of D-*myo*-inositol derivatives through intramolecular pinacol coupling mediated by low-valent titanium reagent. In 1994, Chiara et al.^{4b} and Mioskowski et al.^{4c} independently reported an elegant stereoselective synthesis of inositol derivatives via pinacol coupling of dialdehyde (**1**) using samarium diiodide. However, preparation of **1** requires multistep reactions from D-mannitol^{4b} or L-sorbose^{4c}. We planned to synthesize **1** from readily available diethyl 2,3-*O*-isopropylidene-D-tartrate in a stereo-controlled manner (Scheme 1).

Scheme 1



Scheme 2



Reagents and conditions : a. DIBALH, toluene, -78°C, 2 h, then sodium trimethylphosphonoacetate, DME, -78°C to r.t., 12 h, 74%; b. DIBALH, CH₂Cl₂, -78°C to 0°C, 1 h, 78%; c. Ti(O*i*Pr)₄, D(-)-diethyltartrate, cumene hydroperoxide, MS-4A, CH₂Cl₂, -20°C, 2 days, 73%; d. triphenylphosphine, imidazole, iodine, THF, 0°C, 5 min, then, NH₄Cl, Zn, EtOH, r.t., 30 min, 97%; e. *t*-butylchlorodiphenylsilyl, imidazole, DMF, 0°C to r.t., 18 h, 99%; f. O₃, MeOH, -78°C, 20 min, then dimethylsulfide, -78°C to r.t., 30 min, 94%; g. samarium diiodide, *t*-BuOH, THF, -78°C to r.t., 18 h, 87%

DIBALH reduction of diethyl-2,3-*O*-isopropylidene-*D*-tartrate (**3**) followed by Wittig-Horner reaction in one pot afforded an (*E,E*)-diester (*EE* : *EZ* = 10 : 1)⁵, which was reduced with DIBALH to give the (*E,E*)-bisallyl alcohol (**4**)⁶. Sharpless asymmetric epoxidation of **4** proceeded diastereoselectively to give the bisepoxy alcohol **5**⁷ as the sole product. Substitution of the hydroxy groups in **5** with iodine and successive reduction with Zn⁸ gave **6**⁹ in 97% yield. The protection of both hydroxy groups with *t*-butylchlorodiphenylsilyl and ozonolysis of olefins, followed by reductive workup, gave the known dialdehyde **7**^{4b}, which was transformed to 3,6-di-*O*-*t*-butylidiphenylsilyl-4,5-*O*-isopropylidene-*D*-*myo*-inositol (**8**) according to the reported procedure^{4b}. The overall yield of **8** from **3** through 7 steps was 33 %.

Our current synthetic method should provide easy access to a variety of chiral polyphosphoinositides and other *myo*-inositol polyphosphate derivatives.

References and notes

- Potter, B.V.L.; Lampe, D. *Angew. Chem. Int. Ed. Engl.*, **1995**, *34*, 1933.
- Kapeller, R.; Cantley, L.C. *BioEssays*, **1994**, *16*, 565.
- Sawada, T.; Shirai, R.; Matsuo, Y.; Kabuyama, Y.; Kimura, K.; Fukui, Y.; Hashimoto, Y.; Iwasaki, S. *BioMed. Chem. Lett.*, **1995**, *5*, 2263.
- a) Watanabe, Y.; Mitani, M.; Ozaki, S. *Chem. Lett.*, **1987**, 123. b) Chiara J.L.; Martin-Lomas, M. *Tetrahedron Lett.*, **1994**, *35*, 2969. c) Guidot, J.P.; Le Gall, T.; Mioskowski, C. *Tetrahedron Lett.*, **1994**, *35*, 6671.
- Krief, A.; Dumont, W.; Pasau, P.; Ph. Lecomte, *Tetrahedron*, **1989**, *45*, 3039.
- Barrett, A.G.M.; Kasdorf, K.; Williams, D.J. *J. Chem. Soc., Chem. Commun.*, **1994**, 1781.
- ¹H NMR (500 MHz, CDCl₃): δ 1.41 (s, 6H), 2.37 (br, 2H), 3.15 (brm, 2H), 3.22 (m, 2H), 3.76 (dd, *J* 3.5, 13.0 Hz, 2H), 3.87 (dd, *J* 3.0 and 13.0 Hz, 2H), 3.90 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 26.6, 54.3, 55.3, 60.9, 77.3, 110.8. $[\alpha]_D^{25} +33.8$ (c=1.07, CHCl₃).
- Hayashi, N.; Mine, T.; Fujiwara, K.; Murai, A. *Chem. Lett.*, **1994**, 2143.
- ¹H NMR (500 MHz, CDCl₃): δ 1.45 (s, 6H), 2.29 (d, *J* 7 Hz, 2H), 4.01 (dd, *J* 1.5, 3.0 Hz, 2H), 4.14 (m, 2H), 5.27 (td, *J* 1.5, 10.5 Hz, 2H), 5.38 (td, *J* 1.5, 17.5 Hz, 2H), 5.89 (ddd, *J* 6.0, 10.5, 17.5 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 27.1, 71.8, 79.3, 109.6, 116.9, 136.7. $[\alpha]_D^{25} -3.05$ (c=1.44, CHCl₃).

(Received in Japan 2 November 1995; revised 24 November 1995; accepted 30 November 1995)